Tech glitches overshadow FDA oncology adcomm as a solid majority of advisers vote to keep Roche's Tecentriq in mTNBC
Kicking off three days of reexamining anti-PD(L)-1 accelerated approvals, the FDA’s Oncologic Drugs Advisory Committee started slowly on Tuesday. After a more than hour-long technical …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
